158 related articles for article (PubMed ID: 18406086)
1. Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant.
Shikanov A; Shikanov S; Vaisman B; Golenser J; Domb AJ
Int J Pharm; 2008 Jun; 358(1-2):114-20. PubMed ID: 18406086
[TBL] [Abstract][Full Text] [Related]
2. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of poly(sebacic acid-co-ricinoleic acid) biodegradable delivery system for intratumoral delivery of paclitaxel.
Shikanov A; Vaisman B; Shikanov S; Domb AJ
J Biomed Mater Res A; 2010 Mar; 92(4):1283-91. PubMed ID: 19343769
[TBL] [Abstract][Full Text] [Related]
4. Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel: in vitro release and in vivo toxicity.
Shikanov A; Vaisman B; Krasko MY; Nyska A; Domb AJ
J Biomed Mater Res A; 2004 Apr; 69(1):47-54. PubMed ID: 14999750
[TBL] [Abstract][Full Text] [Related]
5. Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel--effect of additives.
Shikanov A; Ezra A; Domb AJ
J Control Release; 2005 Jun; 105(1-2):52-67. PubMed ID: 15955366
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral delivery of paclitaxel using a thermosensitive hydrogel in human tumor xenografts.
Kim JH; Lee JH; Kim KS; Na K; Song SC; Lee J; Kuh HJ
Arch Pharm Res; 2013 Jan; 36(1):94-101. PubMed ID: 23371803
[TBL] [Abstract][Full Text] [Related]
7. Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres.
Tzafriri AR; Lerner EI; Flashner-Barak M; Hinchcliffe M; Ratner E; Parnas H
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):826-34. PubMed ID: 15701873
[TBL] [Abstract][Full Text] [Related]
8. Prevention of local tumor recurrence following surgery using low-dose chemotherapeutic polymer films.
Liu R; Wolinsky JB; Walpole J; Southard E; Chirieac LR; Grinstaff MW; Colson YL
Ann Surg Oncol; 2010 Apr; 17(4):1203-13. PubMed ID: 19957041
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
Lapidus RG; Dang W; Rosen DM; Gady AM; Zabelinka Y; O'Meally R; DeWeese TL; Denmeade SR
Prostate; 2004 Feb; 58(3):291-8. PubMed ID: 14743469
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and efficacy study of cisplatin and paclitaxel formulated in a new injectable poly(sebacic-co-ricinoleic acid) polymer.
Levy-Nissenbaum E; Khan W; Pawar RP; Tabakman R; Naftali E; Winkler I; Kaufman O; Klapper L; Domb AJ
Eur J Pharm Biopharm; 2012 Sep; 82(1):85-93. PubMed ID: 22732267
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.
Li C; Newman RA; Wu QP; Ke S; Chen W; Hutto T; Kan Z; Brannan MD; Charnsangavej C; Wallace S
Cancer Chemother Pharmacol; 2000; 46(5):416-22. PubMed ID: 11127947
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth.
Lee JY; Kim KS; Kang YM; Kim ES; Hwang SJ; Lee HB; Min BH; Kim JH; Kim MS
Int J Pharm; 2010 Jun; 392(1-2):51-6. PubMed ID: 20298770
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer.
Le Visage C; Rioux-Leclercq N; Haller M; Breton P; Malavaud B; Leong K
J Urol; 2004 Mar; 171(3):1324-9. PubMed ID: 14767342
[TBL] [Abstract][Full Text] [Related]
17. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine.
Doiron A; Yapp DT; Olivares M; Zhu JX; Lehnert S
Cancer Res; 1999 Aug; 59(15):3677-81. PubMed ID: 10446981
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts.
Xie M; Zhou L; Hu T; Yao M
Anticancer Drugs; 2007 Apr; 18(4):459-66. PubMed ID: 17351398
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Springate CM; Jackson JK; Gleave ME; Burt HM
Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]